Review of Retinopathy of Prematurity Management in the Anti‐ VEGF Era: Evolving Global Paradigms, Persistent Challenges and Our AI ‐Assisted Future
Clinical & Experimental Ophthalmology · 2025-12 · 53 (9) · 1202-1217
DOI: 10.1111/ceo.14598 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical & Experimental Ophthalmology, online erschienen am 04.09.2025. Verfasst von Kyle V Marra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, San Diego, California, USA. Hauptthemen laut MEDLINE: Retinopathy of Prematurity, Vascular Endothelial Growth Factor A, Angiogenesis Inhibitors, Artificial Intelligence. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: VitreoRetinal Surgery Foundation, Research to Prevent Blindness.
Abstract (Originalsprache)
Retinopathy of prematurity (ROP) remains a major cause of preventable blindness in premature infants worldwide, with increasing incidence due to advancements in neonatal care. Management of ROP has been revolutionised by anti‐vascular endothelial growth factor (anti‐VEGF) treatments. Pivotal clinical trials have demonstrated the efficacy of anti‐VEGF in the management of Type 1 ROP, while investigation of safety and long‐term effects is ongoing. However, infants with ROP often have persistent avascular retina (PAR) despite treatment and require lifelong monitoring for myopia, glaucoma, amblyopia, strabismus, significant refractive error, retinal tears and detachment and adult reactivation of ROP. Alternative therapeutics, including beta‐blockers, polyunsaturated fatty acids and vitamin A, remain under investigation. Alongside therapeutic advancements, artificial intelligence (AI) and telemedicine programmes have the potential to expand screening accessibility, particularly in underserved regions, and improve inter‐observer variability, though challenges in implementation remain. Together, advanced therapeutics and AI‐enhanced screening hold promise for improving outcomes and reducing ROP‐related blindness globally.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, San Diego, California, USA.
Förderung
- VitreoRetinal Surgery Foundation
- Research to Prevent Blindness
Zitieren
APA
Marra, K. V., Chen, J. S., Nudleman, E., & Robbins, S. L. (2025). Review of Retinopathy of Prematurity Management in the Anti‐ VEGF Era: Evolving Global Paradigms, Persistent Challenges and Our AI ‐Assisted Future. Clinical & Experimental Ophthalmology, 53(9), 1202-1217. https://doi.org/10.1111/ceo.14598
Vancouver
Marra KV, Chen JS, Nudleman E, Robbins SL. Review of Retinopathy of Prematurity Management in the Anti‐ VEGF Era: Evolving Global Paradigms, Persistent Challenges and Our AI ‐Assisted Future. Clinical & Experimental Ophthalmology. 2025;53(9):1202-1217. doi:10.1111/ceo.14598
BibTeX
@article{Marra2025,
author = {Marra, Kyle V and Chen, Jimmy S and Nudleman, Eric and Robbins, Shira L},
title = {Review of Retinopathy of Prematurity Management in the Anti‐ VEGF Era: Evolving Global Paradigms, Persistent Challenges and Our AI ‐Assisted Future},
journal = {Clinical & Experimental Ophthalmology},
year = {2025},
volume = {53},
number = {9},
pages = {1202--1217},
doi = {10.1111/ceo.14598}
}
EUVIMED